Consistent safety

The safety and efficacy of TAKHZYRO (lanadelumab-flyo) were assessed in the HELP study, a 6.5 month pivotal trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo.^1,2